Proviron (Mesterolone): What It Is, How It Compares to Injectable TRT, and What the Evidence Says

What mesterolone is and how it works

Mesterolone is a synthetic androgen built from a DHT backbone with a 1-methyl group added at the C-1 position. That modification is what allows it to survive oral administration without the 17-alpha-alkylation that causes hepatotoxicity in many other oral anabolic-androgenic steroids. Bayer introduced it commercially as Proviron in the 1960s, and it remains available by prescription in a number of countries outside North America, though exact country-by-country approval status changes over time and should be verified locally before assuming access.

Because mesterolone is already a reduced androgen, it does not depend on 5-alpha-reductase conversion, and it cannot be aromatized to estradiol by the CYP19 enzyme complex. That is the mechanistic basis for two commonly repeated claims: that it will not cause estrogen-related side effects such as gynecomastia, and that some clinicians outside the US have used it as an add-on for men on testosterone therapy who have persistent estrogen-related symptoms despite other management. Both claims are plausible given the mechanism, but neither has been tested in a trial designed to confirm clinical benefit as an add-on therapy.

Oral bioavailability is low, commonly cited in the single-digit percent range because of extensive first-pass hepatic metabolism, and the elimination half-life is short enough that twice-daily dosing is typically used to maintain levels. Reported anabolic potency is weak relative to testosterone itself. Older, small studies (including a mid-1970s trial in hypogonadal men) reported mood and cognitive benefits with mesterolone, but that literature predates modern trial standards, generally lacked adequate blinding or placebo control, and should be treated as historical rather than as current evidence. A specific numeric claim from that era should not be repeated here without verification against the original paper.

Why Proviron has no FDA approval in the United States

No manufacturer has filed a New Drug Application for mesterolone with the FDA, and it does not appear in current US testosterone therapy guidelines alongside intramuscular, transdermal, intranasal, and subcutaneous pellet formulations. This is a regulatory fact, not a judgment about the molecule's mechanism: absence of an FDA application means absence of an FDA-reviewed safety and efficacy dataset in the US regulatory sense, regardless of what evidence exists from other countries.

Guideline bodies such as the Endocrine Society have published clinical practice guidance on testosterone therapy that lists approved delivery routes and generally advises against off-label androgens without established efficacy and safety data. Readers should treat any exact quoted language attributed to that guideline with caution unless it has been checked against the current published version, since guideline text is periodically revised. The practical takeaway for a US-based reader is unaffected by the exact wording: mesterolone sits outside the set of options a US clinician can prescribe on-label, and off-label prescribing of an unapproved drug is uncommon and carries added liability and sourcing questions.

Obtaining mesterolone in the US generally means either a compounding pharmacy willing to formulate an unapproved active ingredient (compounded preparations carry their own quality-control and potency-verification uncertainty) or personal importation, both of which carry legal and product-quality risk that FDA-approved testosterone formulations do not carry.

Mesterolone versus testosterone cypionate

Testosterone cypionate is one of the most commonly prescribed injectable testosterone esters in US TRT practice, typically dosed intramuscularly or subcutaneously in the range of 100 to 200 mg every one to two weeks, with a half-life of roughly a week. That dosing produces relatively stable serum testosterone levels between injections.

Decision framework: should mesterolone be part of your plan?

The clinical evidence favoring cypionate over mesterolone for treating hypogonadism is not a close call. A coordinated set of placebo-controlled trials in older men with confirmed low testosterone (the Testosterone Trials) found benefits in sexual function, physical function measures, and mood with testosterone treatment delivering physiologic testosterone levels comparable to what injectable esters achieve. No trial of comparable size or rigor has evaluated mesterolone against placebo or against testosterone therapy for these same outcomes. Readers who want the exact statistics from that trial program should consult the original NEJM publication rather than a secondhand figure, since specific numeric results are easy to misquote.

Cypionate reliably restores serum testosterone to the accepted physiologic male range, something mesterolone's pharmacokinetics do not support as monotherapy.

Mesterolone versus testosterone enanthate

Testosterone enanthate is widely used internationally, with a half-life shorter than cypionate's, and in practice the two esters are generally considered clinically interchangeable by dose. Where enanthate differs meaningfully from mesterolone is downstream metabolism: enanthate delivers testosterone itself, which the body can convert to both DHT and estradiol as needed. Estradiol produced from testosterone contributes to bone mineral density maintenance in men, an effect mesterolone cannot replicate because it produces no estradiol. This is a real theoretical disadvantage of mesterolone for long-term bone health, though it has not been directly studied by comparing mesterolone against enanthate in a bone-outcome trial.

Testosterone propionate: the short-acting ester

Testosterone propionate has the shortest half-life of the commonly used esters, on the order of two days, which requires injections every one to three days to maintain stable levels. It is rarely chosen as a standalone TRT regimen because of this injection burden, though it appears in some multi-ester blends outside standard US pharmacy practice. Most patients and clinicians favor weekly or biweekly dosing with cypionate or enanthate over the frequent injections propionate requires; exact preference percentages from any single survey should be verified before being cited as a general finding.

Testosterone pellets (Testopel)

Subcutaneous testosterone pellets are implanted in-office and provide months of continuous testosterone delivery from a single procedure, avoiding daily or weekly administration entirely. Reported duration of effect and extrusion rates vary across published case series, and a reader considering pellets should ask their prescriber for the specific outcome data behind the product they are being offered rather than relying on a single averaged figure. Pellets deliver bioidentical testosterone through the same downstream metabolic pathways (aromatization to estradiol, reduction to DHT) that mesterolone bypasses, which is the core pharmacologic distinction between the two options. The tradeoffs are procedural: a minor surgical insertion, an upfront cost per implantation, and no ability to quickly lower the dose if side effects appear before the pellets are absorbed.

Does mesterolone actually raise free testosterone in a way that matters?

Proponents of mesterolone point to its affinity for sex hormone-binding globulin as a reason it might displace bound testosterone and raise the free fraction. Laboratory binding studies do show mesterolone binds SHBG with meaningful affinity. The clinical translation of that binding affinity into a symptom benefit is not established. A small crossover study in hypogonadal men found a measurable increase in calculated free testosterone with mesterolone but no significant change on a validated symptom scale, which is exactly the kind of result that argues against treating an SHBG-binding effect as clinically meaningful on its own. Simply titrating the dose of an FDA-approved testosterone product produces larger, more predictable, and better-monitored changes in both total and free testosterone than SHBG displacement from an adjunct androgen.

Side effects and safety considerations

Mesterolone's expected side effects follow from its DHT-derived structure: acne, oily skin, and accelerated male-pattern hair loss in predisposed men. Because it does not aromatize, estrogen-mediated side effects such as gynecomastia and fluid retention are not expected from mesterolone itself, though a man already on testosterone therapy may still experience those from the testosterone component.

An underappreciated risk is that exogenous androgens, including non-aromatizable ones like mesterolone, suppress luteinizing hormone and follicle-stimulating hormone through negative feedback on the hypothalamic-pituitary-gonadal axis. Using mesterolone alone, without concurrent testosterone replacement, can therefore worsen a man's endogenous testosterone deficiency over time rather than correct it. This is a mechanistic point supported by androgen dose-response physiology generally, and it is one of the stronger reasons mesterolone monotherapy is a poor choice for a man being evaluated for hypogonadism.

Because mesterolone is not 17-alpha-alkylated, it is not expected to produce the hepatotoxicity pattern (cholestasis, peliosis hepatis) associated with alkylated oral anabolic steroids. Long-term, controlled human liver-outcome data specific to mesterolone are limited, so "lower expected hepatotoxicity" should be read as a mechanism-based expectation, not a guarantee backed by a large trial.

Mesterolone has historically been marketed in some countries as a treatment for male subfertility. Systematic review evidence in this area has generally not shown a convincing pregnancy-rate benefit, and semen parameter responses across trials have been inconsistent. A reader considering mesterolone for fertility reasons should discuss this evidence gap directly with a reproductive urologist rather than assume benefit from historical marketing claims.

Who should not consider mesterolone

Men with a history of prostate cancer or clinically significant benign prostatic hyperplasia should avoid mesterolone, for the same reason they should approach any androgen therapy cautiously: direct androgen receptor stimulation and the theoretical risk of promoting androgen-sensitive prostate tissue growth. Any man starting an androgen, whether an FDA-approved testosterone product or an unapproved adjunct like mesterolone, should have baseline and follow-up PSA monitoring as part of routine care, consistent with standard urology and endocrinology practice around testosterone therapy.

Choosing among the FDA-approved options

For US-based men with confirmed hypogonadism, the practical choice is generally among testosterone cypionate, testosterone enanthate, transdermal gel, intranasal testosterone, and subcutaneous pellets, not between testosterone and mesterolone. The relevant factors are injection tolerance, how easily the dose can be adjusted if side effects or insufficient response occur, and cost and insurance coverage, which vary enough by plan and pharmacy that a specific price should be confirmed at the time of prescribing rather than assumed from a general figure. Whatever formulation is chosen, routine monitoring of total testosterone, hematocrit, PSA, and a lipid panel at defined intervals after starting therapy, then periodically thereafter, is standard practice, and the exact monitoring schedule should come from the prescribing clinician's current guideline reference rather than a fixed number repeated indefinitely, since guideline recommendations are updated over time.

What is established, what is plausible, and what is not established

Established: mesterolone does not aromatize to estradiol; it is not 17-alpha-alkylated and therefore does not carry the alkylated-steroid hepatotoxicity pattern; it is not FDA-approved in the US; exogenous androgens generally suppress the HPG axis in a dose-related way.

Plausible but unproven: that mesterolone provides a meaningful clinical benefit as an add-on for estrogen-related side effects in men already on testosterone therapy; that its SHBG-binding effect translates into a clinically noticeable symptom improvement; that its lower hepatotoxicity signal in short-term use extends safely to long-term unsupervised use.

Not established: that mesterolone can adequately replace testosterone therapy as monotherapy for hypogonadism; that it improves fertility outcomes in men with subfertility; that its long-term safety profile in humans matches the size and quality of the safety dataset behind FDA-approved testosterone products.